Deciphering the folding transition state structure and denatured state properties of nucleophosmin C-terminal domain

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 12, 2010, Pages 5447-5452

  Scaloni, Flavio ^a   Federici, Luca ^b   Brunori, Maurizio ^a   Gianni, Stefano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Kinetics; Mutagenesis; Protein folding

Indexed keywords

NUCLEOPHOSMIN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; DRUG DESIGN; GENE MAPPING; GENE MUTATION; KINETICS; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN DENATURATION; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN FOLDING; PROTEIN STRUCTURE;

BIOPHYSICAL PHENOMENA; CIRCULAR DICHROISM; HUMANS; KINETICS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; NUCLEAR PROTEINS; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; THERMODYNAMICS;

EID: 77950375373     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0910516107     Document Type: Article

References (51)

1. Falini B, et al. (2009) Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: Molecular basis and clinical implications. Leukemia 23:1731-1743.
2. Grisendi S, Mecucci C, Falini B, Pandolfi PP (2006) Nucleophosmin and cancer. Nat Rev Cancer 6:493-505.
3. Borer RA, Lehner CF, Eppenberger HM, Nigg EA (1989) Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 56:379-390.
4. Falini B, Nicoletti I, Martelli MF, Mecucci C (2007) Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): Biologic and clinical features. Blood 109:874-885. (Pubitemid 46220630)
5. Bolli N, et al. (2009) A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF. Leukemia 23:501-509.
6. Bonetti P, et al. (2008) Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma. J Cell Biol 182:19-26.
7. Di Fiore PP (2008) Playing both sides: Nucleophosmin between tumor suppression and oncogenesis. J Cell Biol 182:7-9.
8. Joerger AC, Fersht AR (2007) Structure-function-rescue: The diverse nature of common p53 cancer mutants. Oncogene 26:2226-2242.
9. Bullock AN, Fersht AR (2001) Rescuing the function of mutant p53. Nat Rev Cancer 1:68-76.
10. Pey AL, et al. (2008) Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. J Clin Invest 118:2858-2867.
11. Scaloni F, Gianni S, Federici L, Falini B, Brunori M (2009) Folding mechanism of the C-terminal domain of nucleophosmin: Residual structure in the denatured state and its pathophysiological significance. FASEB J 23:2360-2365.
12. Schwalbe H, et al. (1997) Structural and dynamical properties of a denatured protein. Heteronuclear 3D NMR experiments and theoretical simulations of lysozyme in 8 M urea. Biochemistry 36:8977-8991.
13. Bai Y, Chung J, Dyson HJ, Wright PE (2001) Structural and dynamic characterization of an unfolded state of poplar apo-plastocyanin formed under nondenaturing conditions. Protein Sci 10:1056-1066. (Pubitemid 32367497)
14. Neira JL, et al. (1996) Towards the complete structural characterization of a protein folding pathway: The structures of the denatured, transition and native states for the association/folding of two complementary fragments of cleaved chymotrypsin inhibitor 2. Direct evidence for a nucleation-condensation mechanism. Fold Des 1:189-208.
15. Shortle D, Meeker AK (1989) Residual structure in large fragments of staphylococcal nuclease: Effects of amino acid substitutions. Biochemistry 28:936-944.
16. Religa TL, Markson JS, Mayor U, Freund SM, Fersht AR (2005) Solution structure of a protein denatured state and folding intermediate. Nature 437:1053-1056. (Pubitemid 41486989)
17. Fersht AR, Matouschek A, Serrano L (1992) The folding of an enzyme. I. Theory of protein engineering analysis of stability and pathway of protein folding. J Mol Biol 224:771-782.
18. Myers JK, Pace CN, Scholtz JM (1995) Denaturant m values and heat capacity changes: Relation to changes in accessible surface areas of protein unfolding. Protein Sci 4:2138-2148.
19. Fersht AR (1999) Structure and mechanism in protein science (Freeman, New York).
20. Abkevich VI, Gutin AM, Shakhnovich EI (1994) Specific nucleus as the transition state for protein folding: Evidence from the lattice model. Biochemistry 33:10026-10036. (Pubitemid 24286081)
21. Fersht AR (1995) Optimization of rates of protein folding: The nucleation-condensation mechanism and its implications. Proc Natl Acad Sci USA 92:10869-10873.
22. Gianni S, et al. (2007) A PDZ domain recapitulates a unifying mechanism for protein folding. Proc Natl Acad Sci USA 104:128-133. (Pubitemid 46067996)
23. Gianni S, et al. (2003) Unifying features in protein-folding mechanisms. Proc Natl Acad Sci USA 100:13286-13291.
24. Itzhaki LS, Otzen DE, Fersht AR (1995) The structure of the transition state for folding of chymotrypsin inhibitor 2 analyzed by protein engineering methods: evidence for a nucleation-condensation mechanism for protein folding. J Mol Biol 254:260-288
25. Sanchez IE, Kiefhaber T (2003) Hammond behavior versus ground state effects in protein folding: Evidence for narrow free energy barriers and residual structure in unfolded states. J Mol Biol 327:867-884
26. Horovitz A (1996) Double-mutant cycles: a powerful tool for analyzing protein structure and function. Fold Des 1:R121-R126.
27. Timasheff SN (1993) The control of protein stability and association by weak interactions with water: How do solvents affect these processes?. Annu Rev Biophys Biomol Struct 22:67-97.
28. McCarney ER, Kohn JE, Plaxco KW (2005) Is there or isn't there? The case for (and against) residual structure in chemically denatured proteins. Crit Rev Biochem Mol Biol 40:181-189.
29. Merchant KA, Best RB, Louis JM, Gopich IV, Eaton WA (2007) Characterizing the unfolded states of proteins using single-molecule FRET spectroscopy and molecular simulations. Proc Natl Acad Sci USA 104:1528-1533.
30. Mok KH, et al. (2007) A pre-existing hydrophobic collapse in the unfolded state of an ultrafast folding protein. Nature 447:106-109. (Pubitemid 46685836)
31. van Gunsteren WF, Bürgi R, Peter C, Daura X (2001) The key to solving the protein-folding problem lies in an accurate description of the denatured state. Angew Chem Int Ed Engl 40:351-355. (Pubitemid 32114874)
32. Ferreon AC, Bolen DW (2004) Thermodynamics of denaturant-induced unfolding of a protein that exhibits variable two-state denaturation. Biochemistry 43:13357-13369.
33. Falini B, et al. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254-266. (Pubitemid 40110814)
34. Falini B, Martelli MP (2009) Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy. Haematologica 94:897-900.
35. Friedler A, et al. (2002) A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci USA 99:937-942. (Pubitemid 34106614)
36. Plaxco KW, Simons KT, Baker D (1998) Contact order, transition state placement and the refolding rates of single domain proteins. J Mol Biol 277:985-994.
37. Daggett V, Fersht AR (2003) Is there a unifying mechanism for protein folding?. Trends Biochem Sci 28:18-25. (Pubitemid 36051002)
38. Karplus M, Weaver DL (1994) Protein folding dynamics: the diffusion-collision model and experimental data. Protein Sci 3:650-668. (Pubitemid 24136370)
39. White GW, et al. (2005) Simulation and experiment conspire to reveal cryptic intermediates and a slide from the nucleation-condensation to framework mechanism of folding. J Mol Biol 350:757-775.
40. Cho JH, Raleigh DP (2006) Denatured state effects and the origin of nonclassical phi values in protein folding. J Am Chem Soc 128:16492-16493.
41. Cho JH, Raleigh DP (2009) Experimental characterization of the denatured state ensemble of proteins. Methods Mol Biol 490:339-351.
42. Fersht AR, Sato S (2004) Phi-value analysis and the nature of protein-folding transition states. Proc Natl Acad Sci USA 101:7976-7981.
43. Scott KA, Alonso DO, Sato S, Fersht AR, Daggett V (2007) Conformational entropy of alanine versus glycine in protein denatured states. Proc Natl Acad Sci USA 104:2661-2666. (Pubitemid 46327936)
44. Dalby PA, Oliveberg M, Fersht AR (1998) Folding intermediates of wild-type and mutants of barnase. I. Use of phi-value analysis andm-values to probe the cooperative nature of the folding pre-equilibrium. J Mol Biol 276:625-646. (Pubitemid 28116134)
45. Uversky VN, Ptitsyn OB (1996) All-or-none solvent-induced transitions between native, molten globule and unfolded states in globular proteins. Fold Des 1:117-122.
46. Grummitt CG, Townsley FM, Johnson CM, Warren AJ, Bycroft M (2008) Structural consequences of nucleophosmin mutations in acute myeloid leukemia. J Biol Chem 283:23326-23332.
47. Wulff JE, Siegrist R, Myers AG (2007) The natural product avrainvillamide binds to the oncoprotein nucleophosmin. J Am Chem Soc 129:14444-14451 (Pubitemid 350171471)
48. Kau TR, Way JC, Silver PA (2004) Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 4:106-117.
49. Santoro MM, Bolen DW (1988) Unfolding free energy changes determined by the linear extrapolation method. 1. Unfolding of phenylmethanesulfonyl alpha-chymotrypsin using different denaturants. Biochemistry 27:8063-8068
50. Silow M, Oliveberg M (1997) Transient aggregates in protein folding are easily mistaken for folding intermediates. Proc Natl Acad Sci USA 94:6084-6086 (Pubitemid 27270640)
51. Jackson SE, Fersht AR (1991) Folding of chymotrypsin inhibitor 2. 1. Evidence for a two-state transition. Biochemistry 30:10428-10435.